SCHEMBL7922247

SCHEMBL7922247

CC(NC(=O)OC(C)(C)C)C(C)(C)C

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA7 P43166 1/20 0.58
CYP2D6 P10635 1/20 0.51
CTSK P43235 9/20 0.49
CTSS P25774 4/20 0.49
CTSL P07711 2/20 0.42
CTSB P07858 2/20 0.42
PREP P48147 1/20 0.42
KMT2A Q03164 1/20 0.41
TRPA1 O75762 1/20 0.41
CA12 O43570 1/20 0.41
CA14 Q9ULX7 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8142343 1.00 CA1 (0.58) CA1CA2CA7CYP2D6CTSK
SCHEMBL254254 1.00 CA1 (0.58) CA1CA2CA7CYP2D6CTSK
SCHEMBL2544316 0.84 CA1 (0.52) CA1CA2CA7CYP2D6CTSK
SCHEMBL1369819 0.84 CA1 (0.52) CA1CA2CA7CYP2D6CTSK
SCHEMBL2544315 0.84 CA1 (0.52) CA1CA2CA7CYP2D6CTSK
SCHEMBL19290013 0.83 CA1 (0.50) CA1CA2CA7CYP2D6CTSK
SCHEMBL12682087 0.83 CA1 (0.50) CA1CA2CA7CYP2D6CTSK
SCHEMBL17700922 0.83 CA1 (0.50) CA1CA2CA7CYP2D6CTSK
SCHEMBL12493535 0.83 CA1 (0.50) CA1CA2CA7CYP2D6CTSK
SCHEMBL17857663 0.83 CA1 (0.50) CA1CA2CA7CYP2D6CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023109926-A1 SPIROOXINDOLE COMPOUND AND USE THEREOF IN PREPARATION OF PROTEASE INHIBITOR AS ANTIVIRAL DRUG 南京药石科技股份有限公司 2023-06-22 WO disclosed
EP-3153515-B1 COMPOUNDS FOR INHIBITING HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AB PHARMA LTD (CN) 2020-08-12 EP disclosed
EP-3153515-A1 COMPOUNDS FOR INHIBITING HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AB Pharma Ltd (CN) 2017-04-12 EP disclosed
US-20070203183-A1 Diaryl piperidines as CB1 modulators SCHERING CORPORATION 2007-08-30 US disclosed
EP-1135365-A1 4-3-SUBSTITUTED-AMINO-CYCLOBUT-3-ENE-1,2-DIONES AND USE FOR INFLUENCING SMOOTH MUSCLE CONTRACTION AMERICAN HOME PRODUCTS CORPORATION (US) 2001-09-26 EP disclosed
WO-2000034230-A1 4-3-SUBSTITUTED-AMINO-CYCLOBUT-3-ENE-1,2-DIONES AND USE FOR INFLUENCING SMOOTH MUSCLE CONTRACTION AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203183-A1 Diaryl piperidines as CB1 modulators CNR1, CNR2, GPR119 CA1 3328/4885CA2 3798/4885CA7 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.